Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
Abstract This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer...
Guardado en:
Autores principales: | Christine M. Cramer-van der Welle, Marjon V. Verschueren, Merel Tonn, Bas J. M. Peters, Franz M. N. H. Schramel, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde, The Santeon NSCLC Study Group |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7d32e5f6f02144ce9a5f775eb813f943 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC
por: M. V. Verschueren, et al.
Publicado: (2021) -
Cost-effectiveness of direct discharge from the emergency department of patients with simple stable injuries in the Netherlands
por: Johanna M van Dongen, et al.
Publicado: (2021) -
Planning in the Netherlands Antilles
por: van Trikt, Humphrey, et al.
Publicado: (2020) -
Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021)